Symbiosis Pharmaceutical Services Expanded Commercial Team
The pharmaceutical company hired five new employees to support its international expansion efforts.
Updated on Oct. 5, 2026 in Healthcare
Live Poll
Do you believe the expansion of pharmaceutical manufacturing capacity is generally good for healthcare access?
Symbiosis Pharmaceutical Services has appointed five new members to its commercial team to drive growth in Asia-Pacific, the Middle East, and Southern Europe. These strategic hires follow a £26 million infrastructure expansion designed to boost the company's aseptic manufacturing capacity.
Why it matters
The company is scaling its operations to meet rising global demand for biologic and injectable therapies. By increasing its commercial footprint, Symbiosis aims to strengthen client relationships across key international markets.
Symbiosis completed a £26 million expansion project to enhance its aseptic manufacturing capabilities. New hires include staff with up to 15 years of industry experience to lead business development initiatives.
The players
Symbiosis Pharmaceutical Services
This is a contract development and manufacturing organization headquartered in Stirling, UK.
Jay Chima
He has joined the organization as the vice president of business development.
Jos Vergeest
He serves as the newly appointed senior business development director for the firm.
Payal Roychoudhury
Based in Glasgow, she brings 15 years of industry experience to the business development team.
Joaquín Pérez Fornieles
Based in Málaga, he joins the business development team with 10 years of professional industry experience.
The details
The new commercial team members include Jay Chima as vice president of business development and Jos Vergeest as senior business development director. They are joined by Payal Roychoudhury, Joaquín Pérez Fornieles, and Annie Shafran, who will manage international client enquiries and sales.
Timeline
The appointment of the new commercial team was announced on October 5, 2026.
Market Landscape
This investment follows the ongoing global investment in CDMO biologic manufacturing capacity, which has driven facility upgrades across the pharmaceutical sector. The move positions Symbiosis to capture greater market share from competitors by scaling infrastructure to meet international demand.
The expansion of manufacturing capacity allows for a more reliable supply of injectable and biologic therapies, potentially increasing product availability for patients worldwide. Clients in the pharmaceutical sector may see improved response times and support as the company bolsters its regional presence.
The takeaway
The company's expansion highlights the shift toward localized support for complex pharmaceutical supply chains. Businesses looking to enter new markets should prioritize staffing local experts who can manage specific regional regulatory and sales requirements.
Further reading
For more on industry growth, visit the Healthcare section.
Source note: This article includes information reported by Pharmabiz.
Live Poll
Do you believe the expansion of pharmaceutical manufacturing capacity is generally good for healthcare access?
